Rwanda is set to begin clinical trials for a vaccine aimed at combating the deadly Marburg virus. The trials will be conducted in collaboration with international health organizations and medical researchers, marking a significant step toward addressing one of the world’s most lethal viruses.

The Marburg virus, which is closely related to the Ebola virus, causes severe hemorrhagic fever and has a high fatality rate. Recent outbreaks in parts of Africa have prompted urgent efforts to find effective vaccines and treatments.

Rwandan health officials confirmed that the vaccine trials will begin in the coming months, with volunteers participating in a controlled environment. The goal is to determine the vaccine’s safety and effectiveness in preventing the virus from spreading.

Authorities emphasized that while there have been no recent cases of Marburg in Rwanda, preparedness is key. By conducting the trials, Rwanda aims to contribute to global efforts in developing a vaccine that can potentially save lives during future outbreaks.

This development comes as part of the country’s broader commitment to strengthening its healthcare system and collaborating with international partners to combat infectious diseases.